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The use of spectroscopy techniques, such as Fourier-transform infrared (FTIR) spectroscopy, 26 
has been a successful method to study the interaction of light with biological materials and 27 
facilitate novel cell biology analysis. Disease screening and diagnosis, microbiological 28 
studies, forensic and environmental investigations make the use of spectrochemical analysis 29 
very attractive due to its low cost, minimal sample preparation, non-destructive nature and 30 
substantially accurate results. However, there is now an urgent need for repetition and 31 
validation of these methods in large-scale studies and across different research groups, which 32 
would bring the method closer to clinical and/or industrial, implementation. In order for this 33 
to succeed, it is important to eliminate the chance of random spectral alterations caused by 34 
inter-individual, inter-instrument and/or inter-laboratory variations. Thus, it is evident that 35 
spectral standardization is crucial for the widespread adoption of these spectrochemical 36 
technologies. By using calibration transfer procedures, different sources of variations can be 37 
normalized into a single model using computational-based methods; therefore, measurements 38 
performed under different conditions can eventually generate the same result, eliminating the 39 
need for a full recalibration. In this paper, we have constructed a protocol for model 40 
standardization using different transfer technologies described for FTIR spectrochemical 41 
applications. This is a critical step towards the construction of a practical spectrochemical 42 









Vibrational spectroscopy has shown great promise as an analytical tool for the 50 
investigation of numerous sample types with wide applications in diverse sectors, such as 51 
biomedicine, pharmaceutics or environmental sciences. Fourier-transform infrared (FTIR) 52 
spectroscopy is one of the preferred techniques for identification of biomolecules through the 53 
study of their characteristic vibrational movements. Using chemometric approaches, the 54 
system is trained to recognize unique spectral features within a sample, so that when 55 
unknown samples are introduced an accurate classification is feasible. Alterations in these 56 
measurement parameters could interfere with the spectral signature and produce random 57 
variations. Therefore, a crucial step is spectral correction, or standardization, which would 58 
provide comparable results and allow system transferability. The idea is that non-biological 59 
variations, such as those arising from different users, locations or instruments, will no longer 60 
affect the classification result; therefore any collected data could be imported into a central 61 
database and handled for further exploration or diagnostic purposes. Several groups and 62 
companies worldwide are developing spectrochemical approaches for diagnosis, 63 
discrimination and monitoring of diseases, as well as for other uses. Combination of multiple 64 
datasets would facilitate the conduction of large-scale studies, which are still lacking in the 65 
field of biospectroscopy. 66 
Sensor-based technologies 67 
Sensor-based technologies are an integral part of daily life ranging from locating 68 
sensor-based technology, such as global positioning system (GPS)1, to image biosensors, 69 
such as X-rays2-5 and γ-rays6-8, which are used extensively for medical applications. Other 70 
powerful approaches that make use of sensor-based technologies toward medical disease 71 
examination and diagnostics include circular dichroism (CD) spectroscopy9-12, ultraviolet 72 
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(UV) or visible spectroscopy13,14, fluorescence15-19, nuclear magnetic resonance (NMR) 73 
spectroscopy20-24 and ultrasound (US) 2,25-28. 74 
Over the last two decades, optical biosensors employing vibrational spectroscopy, 75 
particularly IR spectroscopy, have seen tremendous progress in biomedical and biological 76 
research. A number of studies using the above-mentioned methods have focused on cancer 77 
investigation with malignancies such as brain29-32, breast33-35, oesophagus36,37, skin38-42, 78 
colorectal43-45, lung46-48, ovarian49-53, endometrial50,54,55, cervical56-59 and prostate60-63 cancer 79 
being some of them. Non-cancerous diseases have also been examined, namely 80 
neurodegenerative disorders64-67, HIV/AIDS68, diabetes69-71, rheumatoid arthritis72,73, 81 
cardiovascular diseases74,75, malaria76-78, alkaptonuria79, cystic fibrosis80, thalassemia81, 82 
prenatal disorders82,83, macular degeneration84,85, atherosclerosis75,86 and osteoarthritis87-89. 83 
Limitations 84 
Spectrochemical approaches are advantageous when compared with traditional 85 
molecular methods as they provide a holistic status of the sample under interrogation, thus 86 
generating typical spectral regions widely known as “fingerprint regions”. These methods 87 
have also been shown to be rapid, inexpensive and non-destructive while they also improve 88 
diagnostic performance and eliminate subjective diagnosis (e.g., histopathological diagnosis), 89 
where inter- and intra-observer variability are present90. However, similarly to any other 90 
analytical method, vibrational spectroscopy also comes with some limitations. For instance, 91 
prior to FTIR studies, optimization of instrumental settings, sample preparation and operation 92 
mode also needs to be conducted in order to improve the spectral quality and molecular 93 
sensitivity91-93. Overall, the above-mentioned barriers can be overcome after careful 94 
consideration of the experimental design. 95 
A considerable limitation that is yet under-investigated in the field of spectrochemical 96 
techniques is associated with the difficulties entailed in data conformation and system 97 
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standardization. Currently, there are multiple pilot studies showing promising results but an 98 
approach towards standardization for biological applications is lacking. Random variation 99 
between studies can originate from differences in instrumentation, operators, and 100 
environmental conditions, such as room temperature and humidity. 101 
The main objective of this article is to present a protocol for model standardization, 102 
which can be applied in FTIR spectrochemical techniques to rule out the chance of random 103 
spectral alterations. Inter-individual, inter-instrument, inter-sample and/or inter-laboratory 104 
variations can be a source of unwanted, non-biological alterations, thus leading to incorrect 105 
conclusions. However, for a method to become reliable and clinically translatable, it is 106 
important that measurements performed under different conditions generate comparable 107 
results. The aim of the spectral standardization model presented here is to expedite multi-108 
centre studies with large numbers of samples; this would bring these spectrochemical 109 
techniques closer to clinical implementation and facilitate life-changing decisions. We 110 
describe a protocol that has four main components: (i) sample preparation, (ii) spectral 111 
acquisition, (iii) data pre-processing and (iv) model standardization. The current protocol has 112 
an in-depth insight obtained from cross-laboratory collaborations with leading experts in the 113 
field. This article offers a step-by-step procedure, which can be implemented by a non-114 
specialist in spectrochemical studies. For further information about instrumental and software 115 
options, spectral acquisition steps and data analysis for a range of different analytical systems 116 
the reader is directed towards additional protocols91,94-101. 117 
Applications 118 
Spectrochemical approaches, in combination with computational analysis, have been 119 
proven to be effective for biomedical research through facilitating the diagnosis, 120 
classification, prognosis, treatment stratification and modulation or monitoring of a disease 121 
and treatment. However, these techniques are widely applicable to other fields as well, 122 
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namely food industry102-105, toxicology106-109, microbiology110-115, forensics116-120, 123 
pharmacy108,121,122, environmental and plant science123-125, as well as defence and security126-124 
128. Applications of standardization algorithms vary according to the spectral technique and 125 
sample matrix studied, where mostly are based on Raman and Fourier-transform near-126 




Table 1. Examples of applications involving standardization techniques.  129 
Sample matrix Spectroscopic technique Aim Ref. 
Tissue Raman Standardization of various perturbations on Raman spectra for diagnosis of breast cancer based on snap frozen 
tissues  
129 
 Raman Standardization of spectra acquired in 3 different sites for analysing oesophageal samples based on snap frozen 
tissues 
130 
Cells Raman Standardization of spectra acquired with 4 different instruments for classification of three different cultured 
spore species 
131 
Biofluids FT-NIR Standardization of spectra acquired with 3 different instruments for measuring haematocrit in the blood of 
grazing cattle 
132 
 LC-MS Standardization of spectra acquired with 2 different instruments for mapping rendition times and matching 
metabolite features of subjects diagnosed with small cell lung cancer based on blood serum and plasma 
samples analysis 
133 
Pharmaceutical materials Raman Standardization of spectra acquired with 5 different instruments for analysing various pharmaceutical 
excipients, active pharmaceutical ingredients (APIs) and common contaminants 
134 
 FT-NIR Standardization of spectra acquired with 2 different instruments for simultaneous determination of rifampicin 
and isoniazid in pharmaceutical formulations 
135 
 FT-NIR Standardization of spectra acquired with 2 different instruments for predicting content of 654 pharmaceutical 
tablets 
136 
Food FT-NIR Standardization of spectra acquired with 3 different instruments for predicting parameters in corn samples 136 
137 
 FT-NIR Standardization of spectra acquired with 2 different instruments for predicting vitamin C in navel orange 138 
 FT-NIR Standardization of spectra recorded in 4 different labs for determining moisture, proteins and oil content in soy 
seeds 
139 
 FT-NIR Standardization of spectra acquired by a benchtop and portable instrument for determining total soluble solid 
contents in single grape berry 
140 
 UV-Vis Standardization of visible spectra acquired with 3 different instruments for measuring pH of Sala mango 141 
Plant FT-NIR Standardization of spectra acquired with 2 different instruments for predicting baicalin contents in radix 
scutellariae samples 
137 
 FT-NIR Standardization of spectra acquired by 2 different instruments and in three physical states (powder, filament 
and intact leaf) for determining total sugars, reducing sugars and nicotine in tobacco leaf samples 
142 
 NMR Standardization of spectra acquired with 3 different instruments for authenticity control of sunflower lecithin 143 
Cosmetic CD spectroscopy Standardization of spectra acquired between standard and real-world samples for determining Pb2+ in cosmetic 
samples 
144 
Inorganic substances FT-IR Standardization of interferogram spectra acquired with 2 instruments for classifying acetone and SF6 samples 145  




Model transferability 131 
Transferability models have been previously developed, however this is still an under-132 
investigated field, especially for biomedical applications. An inclusive standardization 133 
protocol that could be implemented in a range of different spectrochemical approaches is of 134 
great need. Differences are present even between identical instruments; for instance, changes 135 
in signal intensity caused by replacement, alignment or ageing of optical and spectrometer 136 
components, natural variations in optics and detectors construction, changes in measurement 137 
conditions (temperature and humidity), changes in physical constitution of the sample 138 
(particle size and surface texture) and operator discrepancies could all lead to wavenumber 139 
shifts and artefacts in the spectra. In all of these cases, prediction errors can become very 140 
large, especially when the whole spectrum is used in the model. Standardization techniques 141 
aim to generate a uniform spectral response under differing conditions, ensuring the 142 
interchangeability of results obtained in different situations, without having to perform a full 143 
calibration for each situation. 144 
Previous standardization methods include the use of simple slope and bias 145 
correction147,148, direct standardization (DS)149-153, piecewise direct standardization 146 
(PDS)147,154-156, piecewise linear discriminant analysis (PLDA)145, guided model 147 
reoptimization (GMR)156, back-propagation neural network (BNN)145, generalized least 148 
squares weighting (GLSW)157, model updating (MU)158,159, orthogonal signal correction 149 
(OSC)160,161, orthogonal projections to latent structures (OPLS)146, wavelet hybrid direct 150 
standardization (WHDS)155, maximum likelihood PCA (MLPCA)162, Shenk and Westerhaus 151 
method (SW)163,164, positive matrix factorization (PMF)165,166, artificial neural networks 152 
(ANN) drift correction167, transfer via extreme learning machine auto-encoder method 153 
(TEAM)168, calibration transfer based on the maximum margin criterion (CTMMC)169, 154 
calibration transfer based on canonical correlation analysis (CTCCA)170 and calibration 155 
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methods, such as wavenumber offset correction, instrument response correction and baseline 156 
correction130. 157 
Direct standardization. DS is one of the most used methods for data standardization. It was 158 
initially proposed to correct relatively large spectral differences between data collected by 159 
two instruments147. In DS, the entire spectrum from a new secondary response (e.g., a 160 
different instrument) is transformed to resemble the spectrum from the primary source (e.g., 161 
original instrument)149. This is performed based on a linear relationship between the data 162 
acquired under different circumstances158: 163 
܁ଵ = ܁ଶ۴           (01) 164 
where ܁ଵ  represents the data acquired for the primary response; ܁ଶ  represents the data 165 
acquired for the secondary response; and ۴ is the transformation matrix that maintains the 166 
relationship between ܁ଵ and ܁ଶ. 167 
 The transformation matrix ۴ is estimated in a least-squares sense by171: 168 
۴ = ܁ଶା܁ଵ           (02) 169 
where ܁ଶା is the pseudo-inverse of ܁ଶ, calculated by: 170 
܁ଶା = ሺ܁ଶ୘܁ଶሻିଵ܁ଶ୘          (03) 171 
in which T stands for the matrix transpose operation. 172 
 Then, when samples are measured under the secondary system, the signals generated 173 
܆ are transformed to resemble the primary system response by158: 174 
܆෡୘ = ܆୘۴           (04) 175 
where ܆෡ is the standardized response for X. 176 
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 Problems related to different background information between instruments can affect 177 
the standardization procedure. To correct for this, the standardization process is usually 178 
adapted with the background correction method171, in which the transformation matrix 179 
described in Eq. 02 is calculated with a background correction factor (۴ୠ) and an additive 180 
background correction vector ܊ୱ as follows: 181 
܁ଵ = ܁ଶ۴ୠ + ૚܊ୱ୘          (05) 182 
where ૚ is an all-ones vector and ܊ୱ is obtained by: 183 
܊ୱ = ܛଵ୫ − ۴ୠ୘ܛଶ୫          (06) 184 
in which ܛଵ୫ is the mean vector of ܁ଵ and ܛଶ୫ is the mean vector of ܁ଶ. 185 
 One of the key steps for DS is the selection of the number of samples to transfer 186 
(called “transfer samples”). These are samples from the primary system (܁ଵ) that will be used 187 
to transform the signal obtained using the secondary system (܁ଶ). Usually, the procedure for 188 
selecting transfer samples is based on sample selection techniques, such as Kennard-Stone 189 
(KS) algorithm172 or leverage147. Subsequently, the number of transfer samples is evaluated 190 
using a validation set through an arbitrary cost function. For quantification applications, a 191 
common cost function is the root-mean-square error of prediction, while for classification one 192 
can use the misclassification rate. 193 
A disadvantage of DS is that each transformed variable is calculated using the whole 194 
spectrum, which carries a high risk of overfitting. The estimation of ۴ in Eq. (02) is a ill-195 
conditioned problem, because the number of variables may be much larger than the number 196 
of standard samples. 197 
Piecewise direct standardization. PDS is another standardization procedure commonly 198 
employed for system transferability. It is based on DS, however it uses windows (e.g., 199 
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wavenumber portions) to make the standardization process more suitable for smaller regions 200 
of the data. When compared to DS, PDS is calculated by using the transformation matrix F 201 
with most of its off-diagonal elements set to zero147. With this, PDS fits minor spectral 202 
modifications not covered by DS. PDS is the technique of preference for correcting smaller 203 
spectral variations, such as small wavelengths shift, intensity variations, and bands 204 
enlargement and reduction147. In addition, an advantage of PDS compared to DS is that the 205 
local rank of each window will be smaller than the rank of the whole data matrix, which 206 
means that the number of standard samples can be smaller, and indeed good results have been 207 
obtained with very few samples. 208 
 One disadvantage of PDS is the need of an additional optimization process, because in 209 
addition to the number of transfer samples, PDS also needs a window size optimization, 210 
which might lead to a risk of overfitting. Herein, the window size optimization is made using 211 
a cost function expressed as the misclassification rate calculated for each window size tested, 212 
being evaluated using a validation set where the window with smaller misclassification is 213 
selected for final model construction. 214 
Experimental Design 215 
A specified number of steps are required for a study using vibrational spectroscopy, 216 
starting from careful experimental design, protocol optimisation and development of 217 
experimental procedure document, sample collection and preparation, spectral collection, pre-218 
processing of the derived information and lastly the use of chemometrics for exploratory, 219 
classification and standardization purposes. FTIR spectroscopy is described in more detail in 220 
this study, however, the standardization protocol described here can be adapted to a range of 221 
techniques, including attenuated total reflection (ATR-FTIR), transmission and transflection 222 
FTIR, near-IR (NIR), UV-visible, NMR spectroscopy and MS. Nevertheless, intrinsic 223 
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features of each technique should be taken into consideration before standardization and the 224 
protocol may change depending on the application of interest. 225 
A number of biological samples can be analyzed with the above-mentioned analytical 226 
methods such as tissues, cytological materials or biological fluids. Sample type and 227 
preparation may differ depending on the technique that is employed each time. For instance, 228 
IR spectroscopy is limited by water interference at the fingerprint region that can mask the 229 
signal of the analyte close to the water peak. This could be addressed with an extra step of 230 
sample drying, in contrast to Raman spectroscopy, for example, where water does not 231 
generate signal in this region. 232 
Typical steps for sample preparation, acquisition of spectra and data pre-processing 233 
are briefly presented here. However, the main focus of this protocol is placed on the 234 
calibration transfer and standardization procedures. Readers are directed to additional 235 
literature for more detailed information regarding sample format and preparation, suitability 236 
of substrates, instrumentation settings or available software packages (Table 2) and 237 
manufacturers91,94-96,101,173-176. 238 
Table 2. Software packages for data standardization. 239 
Software Website Description Availability 
PLS_Toolbox http://www.eigenvector.com/ 
 
MATLAB toolbox for 
chemometric analysis. Contains 
standardization routines using DS, 
PDS, double window PDS, spectral 
subspace transformation, GLSW, 
OSC, and alignment of matrices. 
Commercial 
Unscrambler® X http://www.camo.com/ 
 
Software for multivariate data 
analysis and design of experiments. 
Contains standardization routines 
using interpolation, bias and slope 




Spectral acquisition software with 
data processing features. Contains a 




Chemometrics modelling software. 
Contains standardization routines 





Experimental design: sampling 241 
Sample preparation. Biological samples have been studied extensively with 242 
spectrochemical techniques for disease research. Tissue specimens can be analysed fresh, 243 
snap-frozen or formalin-fixed, paraffin-embedded (FFPE). Fresh or snap-frozen histology 244 
sections are preferable as they are devoid of contaminants whereas FFPE treatment 245 
contributes to characteristic peaks, hindering the biological information. FFPE tissues can be 246 
deparaffinized either by chemical methods (e.g., incubation in xylene, hexane or Histo-Clear 247 
solutions)91, which can alter tissue structures and be inefficient for the complete wax 248 
removal177, or by applying chemometrics (e.g., digital dewaxing)178,179, which keeps the 249 
tissue intact but might introduce artefacts due to over- or under-estimation of the wax 250 
contribution177. 251 
Fixatives, such as ethanol, methanol or formalin, are often used for the preservation of 252 
cytological material, also generating strong peaks and interfering with the spectra; thus, a 253 
washing step is crucial before spectroscopic interrogation. Fixation in tissue or cells for 254 
preservation purposes generates protein cross-linking which can cause changes in the spectra, 255 
especially on the Amide I peak180.  Alternatively, cells can be studied live after washing from 256 
residual medium. 257 
Preparation and pre-treatment of biological fluids depend on the sample type. Some of 258 
the biofluids that have been previously used in spectroscopic studies include blood (whole 259 
blood, plasma or serum), urine, sputum, saliva, tears, cerebrospinal fluid (CSF), synovial 260 
fluid, ascitic fluid or amniotic fluid181-183. A centrifugation step should precede in cases where 261 
the cells present in these fluids are not the focus of the study; the supernatant could then be 262 
kept for further analysis. In blood-based studies, the user should also consider the 263 
anticoagulant of preference (e.g., EDTA, citrate or heparin) as it could generate unwanted 264 
spectral peaks184-186. Careful planning of experiments as well as consistence throughout a 265 
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study are of great importance for the generation of robust results. Samples should be very 266 
stable, since the spectral differences between the data collected under different situations 267 
(e.g., different instruments or temperature) should be directly related to the difference 268 
between the systems and not a change caused by chemical or physical degradation of the 269 
samples. Optimal sample thickness, suitability of substrates and sample formats can differ 270 
from one analytical technique to another and thus the user should decide and tailor these 271 
according to the study’s objective. Another consideration is the number of freeze-thaw cycles 272 
and long-term storage as these could compromise the integrity of the samples184,187. 273 
Preferably, FFPE tissue samples should be analysed after thorough dewaxing and freeze-thaw 274 
cycles or long-term storage avoided since these could result in many confounding factors for 275 
analysis. 276 
Spectral acquisition. Depending on the study’s objective, FTIR spectral information can be 277 
collected using either point spectra or imaging. FTIR spectra can be collected in different 278 
operational modes, namely ATR-FTIR, transmission or transflection. Instrument parameters 279 
such as resolution, aperture size, interferometer mirror velocity and co-additions have to be 280 
optimised before acquisition of spectra to achieve high SNR91,94. Metal surfaces can also be 281 
used to increase the IR signal in a technique known as surface-enhanced IR absorption 282 
(SEIRA)188,189. As water interference can mask biological information in IR spectra, the user 283 
can purge the spectrometer with dry air or nitrogen gas to reduce the instrument internal 284 
humidity, or use computational analysis to remove the water signature. In addition, samples 285 
should be dried until all water content evaporates; however, drying of a sample is not without 286 
consequences, since chemical changes may occur such as loss of volatile compounds. A 287 
background sample is collected regularly to account for any changes in the atmospheric or 288 
instrument conditions. 289 
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For analysing homogenous samples (e.g., biofluids), measurements can be performed 290 
by acquiring spectra on different regions of the centre of a drop and across its borders. In 291 
transmission measurements, the sample can be measured raw or diluted. Usually, 10 spectra 292 
are collected per sample. A higher number of spectral replicas can be performed to decrease 293 
the standard-deviation (SD) between measurements, since the SD is proportion to 1/√݊, 294 
where ݊ is the number of replicas. For heterogeneously distributed samples (e.g., tissues), 295 
spectra should be acquired covering the sample surface as much uniformly as possible, to 296 
ensure that all sources of information is contemplated in the spectral data. Samples replicas 297 
are also recommended at least as triplicates. For precision estimation, at least six replicates at 298 
three levels should be performed. The minimum number of samples for analysis can be 299 
estimated using a power test at an 80% power190. Further details regarding sampling 300 
methodologies for analysing biological materials using FTIR spectroscopy can be found in 301 
our previous protocols91,94. 302 
Experimental design: data quality evaluation 303 
Before processing, the data can be assessed to identify presence of anomalous 304 
behaviours or biased patterns. This can be made initially by visual inspection (e.g., 305 
identification of very anomalous spectra) followed by Hotelling T2 versus Q residuals charts 306 
using only the mean-centred spectra. PCA residuals191 can explored to identify biased 307 
patterns, in which heteroscedastic distributions are signs of biased experimental 308 
measurements; while homoscedastic distributions are associated with good sampling. Also, 309 
mistakes performed during experimental data acquisition can be evaluated by R2 values. 310 
Negative R2 indicates that the sample variance is smaller than the model residuals variance, 311 
which should not happen. SNR can be estimated by dividing the power (ܲ) of signal by the 312 
power of noise, that is SNR = ௦ܲ௜௚௡௔௟ ௡ܲ௢௜௦௘⁄ = ൫ܣ௦௜௚௡௔௟ ܣ௡௢௜௦௘⁄ ൯ଶ, where ܣ is the amplitude; 313 
or by the inverse of the coefficient of variation, when only non-negative variables are 314 
16 
 
measured. Collinearity can be evaluated by calculation of condition number, which is 315 
naturally high for spectral data (high collinearity). 316 
Experimental design: pre-processing 317 
Data pre-processing is employed for maximizing the SNR. This process is 318 
fundamental for correcting physical interfering, such as light scattering, different sample 319 
thickness, different optical paths and instrumental noise. Therefore, the pre-processing step 320 
has fundamental importance to highlight the signal of interest and reduce interfering. 321 
 For standardization applications, the pre-processing step is also important for 322 
reducing differences between the different systems that are used. Before any additional pre-323 
processing, the biofingerprint region should be truncated (e.g., 900-1800 cm-1) before 324 
analysis. This region contains the main absorptions from biochemical compounds and it 325 
suffers minor effects of environmental variability, such as air humidity (free νO-H = 3650–326 
3600 cm-1, hydrogen-bonded νO-H = 3400 – 3300 cm-1) and air CO2 (νsCO2 = 2350 cm-1)192. 327 
Table 3 summarizes the main pre-processing techniques for correcting noise in biologically-328 
derived datasets. 329 
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Table 3. Main pre-processing used for biologically-derived datasets. 330 
Pre-processing Interfering Technique Advantage Disadvantage Optimization 
Savitzky-Golay 
smoothing193 
Instrumental noise ATR-FTIR, FTIR, 
NIR, Raman, NMR, 
UV-Vis 
Corrects spectral noise 
without changing the shape 
of data significantly 
The polynomial order and 
window size for 
polynomial fit affects the 
result 
The polynomial function should 
have an order similar to the 
spectral data (e.g., 2nd order 
polynomial function for IR data) 
and the window size should be an 
odd number and not too small 
(keeping the noise) or too large 
(changing the spectral shape) 
Multiplicative scatter 
correction (MSC)194 
Light scattering (Mie 
scattering), different 
pressure over the sample 
when using ATR or probe, 
different lengths of optical 
path 
ATR-FTIR, FTIR, 
NIR, Raman, NMR, 
UV-Vis 
Corrects light scattering 
maintaining the same 
spectral shape and signal 
scale 
Need of a reference 
spectrum representative of 
all measurements 
The reference spectrum is 
regularly set as the average 
spectrum across all training 
samples 
Standard normal variate 
(SNV)195 
Light scattering (Mie 
scattering), different 
pressure over the sample 
when using ATR or probe, 
different lengths of optical 
path 
ATR-FTIR, FTIR, 
NIR, Raman, NMR, 
UV-Vis, 
fluorescence EEM 
Corrects light scattering 
maintaining the same 
spectral shape 
Creates negative signals 
since the data are 





Light scattering (Mie 
scattering), different 
pressure over the sample 
when using ATR or probe, 




NIR, Raman, NMR, 
UV-Vis 
Corrects light scattering 
and baseline problems; 
highlights smaller spectral 
differences 
Changes the signal scale, 
shifts the data and 
increases noise 
The order of the derivative 
function should be used carefully 
to avoid increased noise (usually 
1st or 2nd order differentiation is 
preferred). The differentiation can 
be coupled to Savitzky-Golay 
smoothing 
Baseline correction196 Background absorption 
interfering 
ATR-FTIR, FTIR, 
NIR, Raman, NMR, 
UV-Vis, MS 
Corrects the baseline 
maintaining the same 
spectral shape 
-- There are many methods for 
baseline correction (e.g., rubber 
band, automatic weighted least 
squares, Whittaker filter). The 
method chosen should be 
maintained consistent for all 
systems used 




Avoids influence of non-
desired signals among the 
The normalization might 




samples between samples at 
important bands, such as 
Amide I and Amide II; and 




 Figure 1 depicts the effect of a pre-processing approach employed for a blood plasma 331 
dataset acquired under different experimental conditions (i.e., different systems and 332 
operators). In this Figure, the reduction of the spectral differences between the systems is 333 
evident after data pre-processing (Savitzky-Golay smoothing, MSC, baseline correction and 334 
normalization). 335 
 336 
Figure 1. Average (a) raw and (b) pre-processed IR spectra for healthy control samples 337 
across three different systems (A, B and C). Average (c) raw and (d) pre-processed IR spectra 338 






After the pre-processing techniques displayed in Table 3, scaling should be employed 341 
as most classification methods require all the variables (e.g., wavenumbers) in the dataset to 342 
be at the same scale in order to work properly. 343 
For spectral data, mean-centring (also referred as “standardization” by Hastie et al.197) 344 
is a very reasonable approach, after which all variables in the dataset will have zero mean. 345 
When data contain values represented by different scales (e.g., after data fusion using both IR 346 
and Raman spectra), block-scaling should be used, where each block of data would have the 347 
same sum-of-squares (normally after mean-centring). 348 
 Another important aspect of pre-processing is the order in which each step is applied. 349 
Pre-processing should be employed in a logical order so that the next pre-processing step is 350 
not affected by the previous one. For example, pure spectral differentiation cannot be 351 
employed before smoothing, since the spectral differentiation will increase the original noise. 352 
Therefore, smoothing should be applied before differentiation. Albeit, Savitzky-Golay routine 353 
incorporates smoothing and spectral differentiation so, in practical terms, these can be 354 
performed together. To summarise, the suggested order of pre-processing is as follows: 355 
1. Spectral Truncation 356 
2. Smoothing 357 
3. Light scattering correction 358 
4. Baseline correction 359 
5. Normalization 360 
6. Scaling 361 
When using different instruments but same type of sample, the pre-processing steps 362 
should be the same for the data acquired under different circumstances. 363 
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Experimental design: data analysis 364 
Sample splitting. Sample splitting is fundamental for constructing a predictive chemometric 365 
model. The splitting procedure can be performed manually or by computer-based 366 
methodologies. Manual splitting can generated biased results, therefore computational-based 367 
split is more recommended. In this case, some strategies includes random selection, 368 
leverage147 or the KS algorithm172. KS works based on Euclidian distance calculation by 369 
firstly assigning the sample with the maximum distance to all other samples to the calibration 370 
set, and then by selecting the samples which are as far away as possible from the selected 371 
samples to this set, until the designed number of selected samples is reached. This ensures 372 
that the calibration model will contain samples that uniformly cover the complete sample 373 
space, where no or minimal extrapolation of the remaining samples are necessary; avoiding 374 
problems of manual or random selection, such as non-reproducibility and non-representative 375 
selection. Usually, the dataset is split with 70% of the samples assigned for training, 15% for 376 
validation and 15% for test. In this case, the test set is dependent on the initial group of 377 
samples measured, and it is not a regular independent test set where a new set of similar 378 
samples are measured. 379 
Exploratory analysis. Exploratory analysis is an important tool to provide an initial 380 
assessment of the data. Using exploratory analysis, the analyst can see the clustering patterns 381 
and then draw conclusions related to the nature of samples, outliers and experimental errors. 382 
One of the most common techniques for exploratory analysis is principal component analysis 383 
(PCA), in which the original data are decomposed into a few principal components (PCs) 384 
responsible for most of the variance within the original dataset. The PCs are orthogonal to 385 
each other and are generated in a decreasing order of explained variance, so that the first PC 386 
represents most of the original data variance, followed by the second PC and so on198. 387 
Mathematically the decomposition takes the form: 388 
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܆ = ܂۾୘ + ۳           (07) 389 
where ܆ represents the pre-processed data (e.g., pre-processed samples’ spectra); ܂ are the 390 
scores; ۾ are the loadings; and ۳ are the residuals. 391 
 The PCA scores represent the variance in the sample direction and they are used to 392 
assess similarities/dissimilarities among the samples, thus detecting clustering patterns. The 393 
PCA loadings represent the variance in the variable (e.g., wavenumber) direction and they are 394 
used to detect which variables show the highest importance for the pattern observed on the 395 
scores. The PCA loadings are commonly employed as a tool for searching spectral markers 396 
that distinguish different biological classes199. The PCA residuals represent the difference 397 
between the decomposed and original data and can be used to identify experimental errors. 398 
Ideally, the PCA residuals should be random and close to zero, representing a heteroscedastic 399 
distribution. Otherwise, they can indicate experimental bias according to a homoscedastic 400 
distribution. 401 
 For standardization applications, PCA is a fast, intuitive and reliable tool to observe if 402 
there are differences between the spectra acquired by different systems. Ideally, if the same 403 
sample is measured under different conditions (different laboratories, instrument 404 
manufacturers or user operators) their PCA scores should be random and completely 405 
superposed. If a discrimination pattern is observed on the PCA scores, then it is indicative 406 
that the data need standardization. Figure 2 illustrates a PCA scores plot from the same 407 
samples (blood plasma of healthy controls) measured using three IR instruments before (Fig. 408 
2a) and after (Fig. 2b) DS. Even though the samples in Fig. 2a are pre-processed, three 409 
different clusters are still evident. After DS the samples measured using different systems are 410 




Figure 2. (a) PCA scores for healthy control samples across three different instruments (A, B 413 
and C) after pre-processing but before DS; (b) PCA scores for healthy control samples across 414 
three different instruments (A, B and C) after DS. The dotted blue circle shows 95 % 415 
confidence ellipse (two-sided).  416 
 417 
Outlier detection. Outlier detection is important to prevent samples, which differ from the 418 
original dataset, from affecting the results using predictive models. Outliers can be attributed 419 
to experimental errors, such as inconsistent sample preparation or spectral acquisition, or to 420 
larger experimental noise, such as Johnson noise, shot noise, flicker noise and environmental 421 
noise. These samples can have large leverage for classification, masking the real signal from 422 
the samples of interest; therefore, it is advised that they be removed from the dataset used to 423 
train the predictive model. 424 
 To detect outliers, techniques such as Jack-knife200, Z-score201 or K-modes 425 
clustering202 can be utilised among others203. One of the most popular and visually intuitive 426 
technique for detecting outliers is the Hotelling T2 vs Q residual test204. In this test, a chart is 427 
created using the Hotelling T2 values in x-axis and the Q residuals in the y-axis, generating a 428 




the distance from the multivariate mean to the projection of the sample onto the PCs205. The 430 
Q residuals represent the sum of squares of each sample in the error matrix, thus measuring 431 
the residues between a sample and its projection onto the PCs205. All samples far from the 432 
origin of this graph are considered outliers and should be removed one at a time, as the PCA 433 
is highly influenced by the samples that are included in the model. Samples with high values 434 
in both Hotelling T2 and Q residuals are the worst outliers; while samples with high values in 435 
only one of these axis are the second worst outliers. Supplementary Method 1 illustrates an 436 
example for outlier detection. Squared confidence limits can be draw based on this graph; 437 
however, this can hinder outlier detection. For example, in squared confidence limits at a 438 
95% level, certain amount of data-points (5%) are set outside these limits. 439 
Classification. Classification techniques are employed for sample discrimination. Using 440 
chemometric analysis, one can distinguish classes of samples based on their spectral features 441 
and then make further predictions based on these. The prediction capability of a classification 442 
model should be evaluated with external samples (unknown samples) through the calculation 443 
of figures of merit, including accuracy (proportion of samples correctly classified considering 444 
true positives and true negatives), sensitivity (proportion of positives that are correctly 445 
identified) and specificity (proportion of negatives that are correctly identified)206. 446 
 There are many types of classification techniques for spectral data. Table 4 447 
summarizes the main classification techniques employed for biospectroscopy applications, 448 







 Table 4. Classification techniques. 454 
Classification Technique Advantage Disadvantage 
Linear discriminant 
analysis (LDA)207 
Simplicity, fast calculation Needs data reduction, does not account 
for classes having different variance 
structures, greatly affected by classes 
having different sizes 
Quadratic discriminant 
analysis (QDA)207 
Fast calculation, accounts for 
classes having different variance 
structures, not much affected by 
classes having different sizes 
Needs data reduction, higher risk of 
overfitting 
Partial least squares 
discriminant analysis 
(PLS-DA)208 
Fast calculation, high accuracy Greatly affected by classes having 
different sizes, needs optimization of the 
number of latent variables (LVs) 
K-Nearest Neighbours 
(KNN)209 
Simplicity, non-parametric, suitable 
for large datasets 
Time consuming, needs optimization of 
the distance calculation method and k 
value, highly sensitive to the “curse of 
dimensionality”197 
Support vector machines 
(SVM)210 
Non-linear classification nature, 
high accuracy 
High complexity, high risk of overfitting, 
needs optimization of kernel function 
and SVM parameters, time consuming 
Artificial neural networks 
(ANN)211 
Non-linear classification nature, 
ability to work with incomplete 
knowledge, high accuracy 
High computational cost, needs 
optimization of the number of neurons 
and layers, no interpretability (“black 
box” model) 
Random forests212 Non-linear classification nature, 
high accuracy, relatively low 
computational cost 
High risk of overfitting, needs 
optimization of the number of trees, no 
interpretability (“black box” model) 
Deep learning 
approaches213 
Non-linear classification nature, 
native feature extraction (e.g., in 
convolutional neural networks 
(CNN)), local spatial coherence 
(CNN), high accuracy 
High computational cost, needs 
hyperparameter optimization, needs large 
datasets, time consuming, no 
interpretability (“black box” model) 
 455 
 When employing classification techniques, one must follow a parsimony order214, 456 
where the simplest algorithms should be used first, reducing the need for more complex 457 
algorithms which would require more optimization steps. An order for using these 458 
classification algorithms is: LDA>PLS-DA>QDA>KNN>SVM>ANN>Random 459 
forests>Deep learning approaches, from the simplest to the most complex. 460 
 Classification algorithms can be coupled to feature extraction and feature selection 461 
techniques in order to reduce data collinearity/redundancy, thus reducing the risk of 462 
overfitting in the classifier training, and speeding up such training, as there are less variables 463 
involved.  An additional benefit of such a feature extraction/selection step is to provide 464 
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spectral markers identification as a “side-effect” (depending on the feature 465 
extraction/selection method applied). For feature extraction, the most popular technique is 466 
PCA. In this case, a PCA is firstly applied to the data, and then the PCA scores are used as 467 
the input variables (instead of the wavenumbers data points) for the classification techniques 468 
mentioned above215. PLS-DA is also a feature extraction technique208, and normally it 469 
performs better than a PCA followed by LDA, as the scores from a PCA does not necessarily 470 
describe the difference between the samples, but rather the variance in the data. In PLS-DA, a 471 
partial least squares (PLS) model is applied to the data in an interactive process reducing the 472 
original variables to a few number of LVs, where a LDA is used for classifying the groups216. 473 
Other discriminant classifiers, in particular QDA, also could be used in this classification step 474 
to circumvent problems observed with LDA. For feature selection, there are many techniques 475 
commonly employed in biological datasets, including genetic algorithm (GA)217 and 476 
successive projections algorithm (SPA)218. The variables (e.g., wavenumbers) selected by 477 
these techniques are used as input variables for the classification models described in Table 2. 478 
An important advantage of GA is its relatively low-computational cost compared to SPA and 479 
reduction of data collinearity. Furthermore, GA-based techniques are intuitive and simple to 480 
understand in the algorithmic sense but they also have a non-deterministic nature and require 481 
optimization of many parameters. SPA’s advantage relies on its deterministic nature, minor 482 
parameter optimization and reduction of data collinearity, however, it is very time 483 
consuming. For hyperspectral imaging, feature selection also can be performed by Minimum 484 
Redundancy Maximum Relevance (mRMR) algorithm219, where the selection process is 485 
based on maximizing the relevance of extracted features and simultaneously minimize 486 
redundancy between them. 487 
 Standardization. Data standardization should be employed when a primary classification 488 
model is built and new data comes to be predicted from a secondary system (different 489 
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laboratory or instrument manufacturers), or when there is a change in instrument components 490 
(e.g., laser, gratings, etc.) or when the data of the chemometric model are acquired under 491 
different circumstances (different analysts, days, instrumental settings, etc.). As previously 492 
mentioned, the most common and reliable methods for data standardization are the DS and 493 
PDS algorithms. These methods can be found in a few software packages (described in Table 494 
3). 495 
Figure 3 summarises the standardization protocol using DS applied to spectra 496 
acquired under different conditions. The first step consists of applying KS algorithm for 497 
selecting the number of transfer samples from the primary system as well as the number of 498 
training samples for the secondary systems, which is ideally 70% of the dataset. Thereafter, 499 
the DS transform generation algorithm is employed to estimate the transform matrix. The 500 
validation set of the secondary system is then used with the classification model of the 501 
primary system to evaluate the optimum number of transfer samples. This optimization step 502 
is repeated depending on the number of transfer samples from the primary system. After this 503 
number is defined, the validation set of the secondary system is finally standardized and the 504 
final classification model is subsequently applied. This procedure is realized with a certain 505 
number of samples measured in all instruments being standardized. This procedure should be 506 
realized in as similar manner as possible to reduce spectral differences. After the model is 507 
standardized and proper validated, new external samples can be measured in any of the 508 




Figure 3. Flowchart for standardization using Direct Standardization (DS). 511 
 512 
 For PDS, an extra step is added after defining the number of transfer samples to 513 
estimate the optimum window size. The dashed region in Fig. 3 is repeated according to the 514 
window size. 515 
 For multi-laboratory studies the flowchart depicted in Fig. 4 illustrates how the 516 
standardization protocol should be employed. 517 
Spectra dataset of the primary system (S1)
Spectra dataset of the secondary system (S2)
Selection of training, validation and 
test sets for S2
Selection of the number of transfer 
samples for S1
Direct standardization transform 
generation algorithm
Standardization of the validation set 
for S2
Application of the primary 
classification model with the 
validation set for S2
Calculation of misclassification rate
Define the optimum number of 
transfer samples
Standardization of the test set for S2
Application of the primary 
classification model with the 






Figure 4. Flowchart for a standardization protocol using different experimental conditions.  519 
 In Fig. 4, spectra acquired under different experimental conditions are used for a 520 
global standardization model. A primary system should be designated and then all spectra 521 
from secondary systems are equally pre-processed, followed by an exploratory analysis to 522 
assess samples’ similarities/dissimilarities, outlier detection, standardization by the method 523 
depicted in Figure 3; the final model construction follows last. With this, all sources of 524 






















▲ CRITICAL Human samples should be collected with appropriate local institutional 530 
review board for ethical approval and adhere to the Declaration of Helsinki principles. 531 
Similarly, for studies involving animals, all experiments should be performed in 532 
accordance with relevant guidelines and regulations. Ethical approval has to be obtained 533 
before any sample collection. 534 
• Optimal cutting temperature (OCT) compound (Agar Scientific, cat. no. AGR1180) 535 
• Liquid nitrogen (BOC, CAS no. 7727-37-9) ! CAUTION Asphyxiation hazard; make 536 
sure room is well ventilated. Causes burns; wear face shield, gloves and protective 537 
clothing. 538 
• Paraplast Plus paraffin wax (Thermo Fisher Scientific, cat. no. SKU502004) 539 
• Isopentane (Fisher Scientific, cat. no. P/1030/08) ! CAUTION Extremely flammable, 540 
irritant, aspiration hazard and toxic; use in a fume hood. 541 
• Distilled water 542 
• PBS (10×; MP Biomedicals, cat. no. 0919610) 543 
• Virkon (Antec, DuPont, cat. no. A00960632) 544 
• Trypsin–EDTA (0.05%, Sigma-Aldrich, Thermo Fisher Scientific cat. no. 25300054) 545 
 546 
Anticoagulants 547 
• EDTA (Thermo Fisher Scientific, BD Vacutainer, cat. no. 02-687-107 ) 548 
• Sodium citrate (Thermo Fisher Scientific, BD Vacutainer) 549 
• Lithium/sodium heparin (Thermo Fisher Scientific, BD Vacutainer) 550 
 551 
Fixative and preservative agents 552 
• Formalin, 10% (vol/vol; Sigma-Aldrich, cat. no. HT501128) ! CAUTION Potential 553 
carcinogen, irritant and allergenic; use in a fume hood. 554 
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• Ethanol (Fisher Scientific, cat. no. E/0600DF/17) 555 
• Methanol (Fisher Scientific, cat. no. A456-212) ! CAUTION Toxic vapours; use in a 556 
fume hood. 557 
• Acetone (Fisher Scientific, cat. no. A19-1) ! CAUTION Acetone vapors may cause 558 
dizziness; use in a fume hood. 559 
• ThinPrep (PreservCyt Solution, Cytyc Corp) 560 
• SurePath (Becton Dickinson Diagnostics) 561 
 562 
Dewaxing agents 563 
• Xylene (Sigma-Aldrich, cat. no. 534056) ! CAUTION Potential carcinogen, irritant and 564 
allergenic; use in a fume hood. 565 
• Histo-Clear (Fisher Scientific, cat. no. HIS-010-010S) ! CAUTION It is an irritant. 566 
• Hexane (Fisher Scientific, cat. no. 10764371) ! CAUTION Extremely flammable liquid, 567 
can cause skin irritation; use protective equipment as required; use in a fume hood. 568 
 569 
EQUIPMENT 570 
• Microtome (Thermo Fisher Scientific, cat. no. 902100A; or cat. no. 956651) 571 
• Wax dispenser (Electrothermal, cat. no. MH8523B) 572 
• Sectioning bath (Electrothermal, cat. no. MH8517) 573 
• Centrifuge (Thermo Fisher Scientific, cat. no. 75002410) 574 
• Desiccator (Thermo Fisher Scientific, cat. no. 5311-0250) 575 
• Desiccant (Sigma-Aldrich, cat. no. 13767) 576 
• Laser power meter (Coherent, cat. no. 1098293) 577 
• Spectrometer 578 




▲ CRITICAL Substrate should be carefully chosen depending on the spectrochemical 581 
approach that will be used. 582 
• Low-E slides (Kevley Technologies, CFR) 583 
• BaF2 slides (Photox Optical Systems) 584 
• CaF2 slides (Crystran, cat. no. CAFP10-10-1) 585 
• Silicon multi-well plate (Bruker Optics) 586 
• Glass slides (Fisher Scientific, cat. no. 12657956) 587 
• Quartz slides (UQG Optics, cat. no. FQM-2521) 588 
• Aluminum-coated slides (EMF, cat. no. AL134) 589 
• Mirrored stainless steel (Renishaw, cat. no. A-9859-1825-01) 590 
 591 
REAGENT SETUP 592 
Tissue For FFPE tissue, the excised specimen is immersed in fixative (e.g., formalin), 593 
dehydrated in ethanol, cleared in xylene and embedded in paraffin wax. Specimens can then 594 
be stored indefinitely at room temperature. For snap-frozen tissue, the specimen is immersed 595 
in OCT, followed by cooling of isopentane with liquid N2. 596 
▲ CRITICAL Snap-frozen tissue should be thawed before analysis. Spectroscopic analysis 597 
should be performed directly after excision in case of fresh tissue to avoid sample 598 
degradation. 599 
Cells Cells can be treated with a suitable fixative or preservative solution or studied alive. 600 
▲ CRITICAL In case cells are fixed or stored in a preservative solution, a number of 601 
washing steps using centrifugation should be followed prior to spectroscopic analysis to 602 
remove unwanted signature. If cells are studied alive, optimum living conditions (e.g., growth 603 
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medium, temperature and pH) should be maintained; washing of live cells from medium is 604 
also necessary. 605 
Biofluids Biofluids can be collected in designated, sterile tubes using standard operating 606 
procedures to achieve uniformity of performance. Preparation of biofluids depends on the 607 
sample type and the experiment’s objective. If cellular material is not directly studied, it 608 
should be removed from the biofluid before storage. Biofluids can be analysed right after 609 
their collection or stored at a -80°C freezer. 610 
▲ CRITICAL If biofluids have been stored in a freezer, it is essential that they are fully 611 
thawed before acquiring aliquots for spectroscopic analysis. 612 
▲ CRITICAL Users are advised to store biofluids in smaller, single-use aliquots at -80°C to 613 
avoid repeated freeze-thaw cycles. 614 
 615 
EQUIPMENT SETUP 616 
The user can choose from a range of different instrumental setups and spectral acquisition 617 
modes. General information about FTIR systems is provided below. For more details about 618 
equipment setup see refs.91,94,95. 619 
The FTIR spectrometer can be left on for long periods of time. Before spectral acquisition, 620 
the user should check the interferogram signal for amplitude and position and keep a record 621 
of the measurements. 622 
▲ CRITICAL For detectors that require a prior cooling step using liquid nitrogen (e.g., 623 
mercury cadmium telluride (MCT) detectors), the signal should be allowed to stabilize for 624 
approximately 10 min before data collection. 625 
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▲ CRITICAL In case that the interferogram signal deviates from the last measurement, re-626 
alignment or part replacement may be required. 627 
Software: Software for spectral acquisition is typically provided by the manufacturer. 628 
Software packages for spectral analysis and data standardization are provided in Table 3. 629 
PROCEDURE 630 
Sample preparation 631 
1| Prepare the biological samples for spectrochemical analysis using the following steps: 632 
option A for FFPE tissue samples, option B for snap-frozen or fresh tissue samples, option C 633 
for cells and option D for biofluids. 634 
▲ CRITICAL Sample preparation is briefly presented in this protocol. More details about 635 
sample preparation can be found in ref.91,94,95. 636 
(A) Tissue (FFPE) ● TIMING 1-1.5 h 637 
(i) Acquisition of FFPE tissue blocks. 638 
 (ii) Whole tissue block has to be sectioned using a microtome to obtain tissue sections 639 
at desired thickness (2-10 μm). 640 
▲ CRITICAL Cooling of the tissue on an ice block allows easier sectioning. 641 
 (iii) Tissue ribbons are floated in a warm H2O bath and then deposited onto the 642 
substrate of choice. 643 
 (iv) The tissue slide is then allowed to dry either at room temperature (30 min) or in a 644 
60°C oven (10 min). 645 
▲ CRITICAL The tissue slide may be dried in the oven for longer periods of time, 646 
depending on the type of tissue, to ensure optimal melting of the wax initially. 647 
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 (v) Dewaxing is then performed by three sequential immersions in a dewaxing reagent 648 
such as fresh xylene, Histo-Clear solution or hexane (at least 5 min).  649 
▲ CRITICAL Thorough dewaxing is important for eliminating all spectral peaks attributed 650 
to paraffin. 651 
 (vi) Tissue slide is immersed in acetone or ethanol (5 min) to remove the xylene and 652 
then left to air-dry. 653 
■ PAUSE POINT Slides can be stored in a desiccator at room temperature for at least 1 654 
year. 655 
(B) Tissue (Snap-frozen or fresh) ● TIMING 2 h + drying time (3 h for FTIR only) 656 
▲ CRITICAL Snap-frozen tissue can be stored at -80°C for several months.  657 
▲ CRITICAL For fresh tissue, proceed to step 1B(iii). 658 
 (i) Acquire snap-frozen tissue from freezer and place onto a cryostat (30 min) to allow 659 
the tissue to reach the cryostat’s temperature (-20°C). 660 
(ii) Tissue block can be sectioned using the cryostat to obtain tissue sections at desired 661 
thickness (8-10 μm). 662 
 (iii) The tissue sections are deposited onto an appropriate substrate before spectra are 663 
collected. 664 
▲ CRITICAL For FTIR studies the tissue sections need to dry for at least 3 h to remove the 665 
H2O interference with the IR spectra. 666 




(C) Cells (fixed or live) ● TIMING 30 min + desiccation time (3 h for FTIR only) 669 
▲ CRITICAL If cells are studied live proceed to step 1C(ii) 670 
 (i) Fixed cells need to be washed from the fixative or preservative solution to remove 671 
any spectral interference in the fingerprint region. Three sequential washes with distilled H2O 672 
or PBS have been shown to remove unwanted peaks. 673 
 (ii) Live cells in suspension have to be detached from the growth substrate using 674 
trypsin and then washed from the medium and trypsin with PBS (×3 times). 675 
▲ CRITICAL All reagents should be warmed to 37°C to reduce the shock to cells and 676 
maintain morphology. 677 
 (iii) After the final wash, the remaining cell pellet is resuspended in distilled H2O and 678 
mounted on a substrate of choice. 679 
▲ CRITICAL The final suspension of cells should be evenly deposited on the slide either 680 
by cytospinning or by micro-pipetting. 681 
▲ CRITICAL For FTIR studies the sample needs to dry for at least 3 h. 682 
(D) Biofluids (frozen or fresh) ● TIMING 5 min + thawing (20 min) + drying (1-1.5 h)  683 
▲ CRITICAL If biofluids are analysed fresh, immediately after collection, continue to step 684 
1D(ii). 685 
 (i) Acquire biofluids from the -80°C freezer and allow them to fully thaw. 686 
 (ii) Mix or gently vortex the sample before obtaining the desired volume for analysis. 687 
▲ CRITICAL Only a small amount of the biofluid is typically required for spectroscopic 688 
studies (1-100 μL). However, this depends and should be tailored according to the study and 689 
experimental design. 690 
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 (iii) Deposit the biological fluid onto an appropriate substrate. 691 
▲ CRITICAL For ATR-FTIR spectroscopic studies, an alternative option is to deposit the 692 
sample directly on the ATR crystal instead of a substrate if the instrumentation setting allows 693 
(i.e., if crystal is facing upwards). However, if the sample is sufficiently thick (>2-3 μm) to 694 
avoid substrate interference, then the use of a holding substrate is advantageous as it allows 695 
measurements from multiple locations as well as longer storage. 696 
▲ CRITICAL For FTIR studies the sample needs to dry adequately before spectroscopic 697 
analysis (50 μl dry within approximately 1 h at room temperature). Drying can be sped up by 698 
using a gentle stream of air. 699 
Spectral acquisition 700 
2| Spectrochemical information can be collected as follows for FTIR spectroscopy. 701 
▲ CRITICAL Spectral acquisition is briefly presented in this protocol. More details can be 702 
found in ref.91,94,95. 703 
FTIR spectroscopy ● TIMING 2 - 5 min per spectrum 704 
(i) Settings should be optimised before a new study to increase the SNR (see 705 
‘Experimental: spectral acquisition’). 706 
▲ CRITICAL Some of the parameters that need to be adjusted include the resolution, 707 
spectral region of interest, co-additions, aperture size, interferometer mirror velocity, and 708 
interferogram zero-filling. 709 
 (ii) Depending on the sampling mode that has been chosen (ATR-FTIR, transmission 710 
or transflection), sample is deposited onto the appropriate holding substrate. 711 
 (iii) Load the sample and visualise the region of interest; information can then be 712 
acquired either as point map or as image maps. 713 
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▲ CRITICAL Typically, 5-25 point spectra are collected per sample while for image maps 714 
the step size should be the same or smaller than the selected aperture size divided by two. 715 
Sampling can be performed with 6 replicates in 3 levels. 716 
▲ CRITICAL A background spectrum should be acquired before every sample to account 717 
for atmospheric changes. 718 
▲ CRITICAL To improve reproducibility and decrease differences between the data 719 
collected by different operators, the spectral resolution should be set constant, since it can 720 
cause major differences between data collected across different experimental setups. 721 
▲ CRITICAL The pressure applied on the sample in the ATR mode affects the signal 722 
intensity (i.e., absorbance) between data collected by different instruments and operators. 723 
Thus, the pressure applied on the sample should be as closest as possible across different 724 
experimental setups to reduce differences between the spectra collected. 725 
■ PAUSE POINT Save the acquired data in a database until further analysis. 726 
Data quality evaluation ● TIMING 15 min – 4 h (depending on the size of the dataset) 727 
▲ CRITICAL Before pre-processing, the raw data can be evaluated using some quality tests 728 
to identify anomalous spectra or biased patterns. This can be made by visual inspection of the 729 
collected spectra followed by Hotelling T2 versus Q residuals charts using only the mean-730 
centred data, and analysis of PCA residuals. 731 
Data pre-processing ● TIMING 15 min – 4 h (depending on the size of the dataset) 732 
▲ CRITICAL Steps 1-6 below can vary depending on the nature of the dataset. Table 1 733 
provides more details about these pre-processing steps. In case of an ATR-FTIR dataset 734 
acquired under different experimental conditions, the pre-processing method should follow 735 
this order: 736 
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1. Cutting at biofingerprint region (900-1800 cm-1). The spectra should be truncated 737 
to the biofingerprint region to reduce atmospheric interference. 738 
2. Savitzky-Golay smoothing for removing spectral-noise. Window size varies 739 
according to the size of the spectra dataset (e.g., wavenumber). The window size 740 
should be an odd number and the analyst should vary it from 3 to 21 and observe how 741 
the spectra change (in shape) and how the noise is reduced. The smallest window that 742 
removes the noise considerably whilst maintaining the original spectral shape should 743 
be used. Using a spectral resolution of 4 cm-1, the biofingerprint region (900-1800 cm-744 
1) usually contains 235 wavenumbers. In that case, a window size of 5 points should 745 
be used. The polynomial order for Savitzky-Golay fitting should be 2nd order for IR 746 
spectroscopy due to the band shape. 747 
3. Light scattering correction using either multiplicative scatter correction (MSC), 748 
SNV or 2nd derivative. The user should prioritize MSC or SNV as these methods 749 
maintain the spectral scale and original spectral shape. In case of unsatisfactory 750 
results, 2nd derivative should be then employed. 751 
4. Baseline correction using automatic weighted least squares or rubber band 752 
baseline correction. If spectral differentiation is applied as light scattering correction 753 
method, baseline correction is not necessary. 754 
5. Normalization to the amide I peak, amide II peak or vector normalization (2-Norm, 755 
length = 1) should be applied to correct different scales across spectra (e.g., due to 756 
different sample thicknesses when using FTIR in transmission mode). 757 
6. Scaling (i.e., for each variable, mean-centring followed by division by the 758 
variable standard deviation). In case of data fusion, block-scaling should be used. 759 
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Data analysis 760 
(A) Exploratory analysis. ● TIMING 1h – 4 d (depending on the data size) 761 
Exploratory analysis should be primarily conducted using PCA. The PCA scores plot (PC1 vs 762 
PC2) should be used for identification of the need of a standardization procedure. 763 
(B) Outlier detection. ● TIMING 1h – 1 d (depending on the data size) 764 
Apply PCA to the dataset and then estimate the Q residuals and Hotelling T2 values. Use the 765 
chart of Q residuals versus Hotelling T2 to identify outliers. The outliers (e.g., cosmic rays, 766 
artefacts, low signal spectra and substrate only (non-tissue) spectra) should be removed from 767 
the data set before proceeding to the next steps. 768 
(C) Sample split. ● TIMING 1 – 4 h (depending on the data size) 769 
Sample split should be performed before construction of standardization of multivariate 770 
classification models. The samples can be split into training (70%) and test (30%) sets, using 771 
a cross-validated model; or split into training (70%), validation (15%) and test (15%) sets 772 
without using cross-validation. To maintain consistency and account for a well-balanced 773 
training model, KS algorithm should be employed. 774 
(D) Standardization. ● TIMING 1h – 4 d (depending on the data size) 775 
▲ CRITICAL Standardization methods should be employed in the following order: DS > 776 
PDS. The data from the secondary response should be separated into training (70%), 777 
validation (15%) and test (15%) sets using KS algorithm. The number of transfer samples 778 
should be firstly optimized using the validation set from the secondary response. Then, when 779 
employing PDS, the window size should be optimized according to the size of the dataset. 780 
(i) DS should be employed varying the number of transfer samples from 10-100% of 781 
the training set from the primary system. The validation set from the secondary instrument 782 
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should be used to find the optimum number of transfer samples using the misclassification 783 
rate as cost function. 784 
(ii) PDS should be employed using the optimum number of samples found with DS. 785 
Different window sizes should be tested using the validation set from the secondary system 786 
with the misclassification rate as cost function. The window size should vary from 3-29 for a 787 
spectral set with resolution of 4 cm-1 in the biofingerprint region (235 variables). 788 
(E) Model construction. ● TIMING 1h – 4 d (depending on the data size) 789 
▲ CRITICAL Feature extraction (e.g., by means of PCA) or feature selection (e.g., by 790 
means of GA or SPA) should be employed to reduce data collinearity and speed up data 791 
processing and analysis time. PLS-DA is already a feature extraction method, thus the 792 
performance of prior feature extraction is not necessary in this case. The classification 793 
technique employed must follow a parsimony order: LDA>PLS-794 
DA>QDA>KNN>SVM>ANN>Random forests>Deep learning approaches. 795 
(i) Apply the feature extraction or selection technique. The optimization of the 796 
number of PCs during PCA can be performed using an external validation set (15% of the 797 
original data set) or using cross-validation (leave-one-out for small dataset [≤20 samples] or 798 
venetian blinds [sample splitting: 10] for large datasets [>20 samples]). GA should be 799 
realized three-times starting from different initial populations and the best result using an 800 
external validation set (15% of the original data set) should be used. Cross-over probability 801 
should be set for 40% and mutation probability should be set for 1-10% according to the size 802 
of the dataset. 803 
(ii) The classification method should be employed using optimization with an external 804 
validation set or cross-validation, especially for selecting the number of latent variables of 805 
PLS-DA and the kernel parameters for SVM. The kernel function for SVM should be RBF 806 
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kernel, due to its adaptation to different data distributions. To avoid overfitting, cross-807 
validation should be always performed during model construction to estimate the best RBF 808 
parameters. 809 
? TROUBLESHOOTING 810 
Spectral acquisition: Spectral resolution, spectral range, SNR and signal aperture should be 811 
optimized during experimental setup. Operators using different systems should try to keep 812 
these parameters constant to reduce spectral differences. 813 
Data pre-processing: To reduce spectral differences, the same data pre-processing should be 814 
applied for spectra acquired in different systems. 815 
Standardization: To improve the prediction capability of the classification model, the 816 
primary system used should be the one with highest spectral resolution and smallest noise, 817 
since all data from the secondary systems will be standardized to this pattern. 818 
● TIMING 819 
Sample preparation:  820 
(A) Tissue (FFPE): 1-1.5 h 821 
(B) Tissue (Snap-frozen or fresh): 2 h + drying time (3 h) 822 
(C) Cells (fixed or live): 30 min + desiccation time (3 h) 823 
(D) Biofluids (frozen or fresh): 5 min + thawing (20 min) + drying (1-1.5 h)  824 
Spectral acquisition:  1 s – 5 min per spectrum (depending on the instrument and spectral 825 
acquisition configurations) 826 
Data pre-processing: 15 min – 4 h 827 
Data analysis: 828 
(A) Exploratory analysis: 1 h – 4 d 829 
(B) Outlier detection: 1 h – 1 d 830 
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(C) Standardization: 1 h – 4 d 831 
(D) Model construction: 1 h – 4 d 832 
ANTICIPATED RESULTS 833 
A pilot study was conducted to evaluate the effect of different instrument 834 
manufacturers and operators towards spectral acquisition of healthy controls and ovarian 835 
cancer samples based on blood plasma (5 healthy controls with 10 spectra per sample; 5 836 
ovarian cancers with 10 spectra per sample) for a binary classification model using ATR-837 
FTIR spectroscopy. All specimens were collected with ethical approval obtained at Royal 838 
Preston Hospital UK (16/EE/0010). Table 4 summarizes the experimental conditions in 839 
which the experiments were performed. 840 
Table 4. Experimental conditions for pilot study. 841 








A  1 4000-400 cm-1 32 4 cm-1 23.0ºC 23% 
 2 4000-400 cm-1 32 4 cm-1 23.4ºC 26% 
B  1 4000-400 cm-1 32 4 cm-1 24.0ºC 26% 
 2 4000-400 cm-1 32 4 cm-1 24.9ºC 24% 
C  1 4000-400 cm-1 48 4 cm-1 22.5ºC 28% 
 2 4000-400 cm-1 48 1 cm-1 22.8ºC 26% 
 842 
 Instrument A and B were Bruker Tensor 27 with an HELIOS ATR attachment while 843 
instrument C was an ATR-FTIR Thermo Scientific Nicolet iS10. The spectra were collected 844 
for the same types of samples within three different days (operator 1: instrument A in day 1, 845 
instrument B in day 3, and instrument C in day 2; operator 2: instrument A in day 2, 846 
instrument B in day 1, and instrument C in day 3) and across two different laboratories 847 
(instrument A and B in laboratory 1 and instrument C in laboratory 2). Each operator 848 
prepared the samples individually from the same bulk, and measured them individually. 849 




(A) Effect of different instruments  852 
 Three different ATR-FTIR spectrometers were used to analyse the samples. Data 853 
were pre-processed by truncating at the biological fingerprint region (900-1800 cm-1), 854 
followed by Savitzky-Golay smoothing (window of 15 points, 2nd order polynomial 855 
function), MSC, baseline correction using automatic weighted least squares and vector 856 
normalization (2-Norm, length = 1). Each data set (A, B and C) was pre-processed 857 
individually. The raw and pre-processed spectra for healthy controls and ovarian cancer 858 
samples are depicted in Supplementary Material 1. All spectra collected by the three 859 
instrument maintained the same spectral shape, indicating that the chemical information 860 
stayed the same; however, large differences between the absorbance intensity were observed 861 
between instrument C and the others (A, B), being caused due to different pressures applied 862 
on the sample in the ATR module. The pressure applied to keep the sample in contact with 863 
the ATR crystal directly affects the spectral signal intensity, which for instrument A and B 864 
(same manufactures) were somewhere controlled by a contra weight, while for instrument C 865 
the pressure was set based on a mechanical screw on the device, thus being biased by the 866 
operator usage. The absorbance intensity variation between A and B is observed for this same 867 
reason, but in a minor scale. Outlier detection was performed using a Hotelling T2 versus Q 868 
residual test (Supplementary Material 1). 869 
(i) Classification. Classification was performed using PCA-LDA (10 PCs, explained 870 
variance of 99.21%). Fig. 5a depicts the discriminant function (DF) score plot for PCA-LDA 871 
using only the primary system (ATR-FTIR A). As observed, there is an almost perfect 872 
separation between the samples from the two classes (accuracy = 100%, sensitivity = 100%, 873 
specificity = 100%). However, when the spectra acquired using instruments B and C are 874 
predicted using the model for A, the results decreased significantly (accuracy = 66.7%, 875 
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sensitivity = 83.2%, specificity = 48.9%) (Fig. 5b), necessitating the use of a standardization 876 
procedure. 877 
 878 
Figure 5. (a) DF plot of the PCA-LDA model for the primary system; (b) DF plot of the 879 
PCA-LDA model for the primary system predicting the samples from the secondary systems. 880 
 881 
(ii) Standardization. Standardization was employed using both DS and PDS in order 882 
to compare the two methods. The number of transfer samples for DS was optimized 883 
according to the misclassification rate obtained for the validation set using the secondary 884 
system (Fig. 6a). An optimum number corresponding to 80% of the samples in the training 885 
set of the primary system (55 transfer samples) was obtained, resulting to a misclassification 886 
rate of 22.2% in the validation set of the secondary system. This improved the accuracy 887 
(77.8%) and specificity (80.0%). Sensitivity decreased to 75.0%, which is an acceptable 888 
value. The results after DS are better balanced than without standardization. Fig. 6b shows 889 
the DF plot for the PCA-LDA model using the training of the primary system and prediction 890 
with the secondary system after DS. 891 
 PDS was also applied. The number of transfer samples was maintained as 55 (80% of 892 




secondary system. An optimum window size of 23 wavenumbers was selected with a 894 
misclassification rate of 25.9% (Fig. 6c). The accuracy, sensitivity and specificity using PDS 895 
were 74.1%, 71.4% and 75.0%, respectively. The DS presented a slightly higher performance 896 
than PDS for this dataset. However, DS generated some outliers not observed before, while 897 
PDS did not. Thus, in general, PDS provided a better standardization of the data. The PCA-898 
LDA DF plot after PDS is depicted in Fig. 6d. 899 
 900 
Figure 6. (a) Misclassification rate in % for the validation set of the secondary system 901 
varying the number of transfer samples in % from the primary system for DS optimization; 902 
(b) DF plot of the PCA-LDA model for the primary system predicting the validation set from 903 
the secondary system after DS; (c) Misclassification rate in % for the validation set of the 904 





LDA model for the primary system predicting the validation set from the secondary system 906 
after PDS.  907 
(B) Effect of different operators 908 
The effect of different user operators acquiring spectra from the same samples using 909 
the same instruments was also evaluated. Similarly to before, data were pre-processed by 910 
cutting the biological fingerprint region (900-1800 cm-1), followed by Savitzky-Golay 911 
smoothing (window of 15 points, 2nd order polynomial function), MSC, baseline correction 912 
using automatic weighted least squares and vector normalization (2-Norm, length = 1). Each 913 
dataset was pre-processed individually. All raw and pre-processed spectra varying operators 914 
are depicted in Supplementary Material 1. Outlier detection was performed using a Hotelling 915 
T2 versus Q residual test (Supplementary Material 1). The PCA scores plots for the pre-916 
processed spectra are depicted in Supplementary Material 1. The main difference between the 917 
operators was observed for instrument C (Supplementary Material 1, Figure S5e), since the 918 
spectral resolutions used by them were different, which can cause major data distortion.  919 
 (i) Classification. Classification was performed using PCA-LDA (10 PCs, explained 920 
variance of 98.62%). Fig. 7a depicts the DF score plot for PCA-LDA using only the primary 921 
system (Operator 1). There is a significant separation between the samples from the two 922 
classes (accuracy = 88.4%, sensitivity = 77.3%, specificity = 100%). When the spectra 923 
acquired by Operator 2 are predicted using the model for Operator 1, the results decreased 924 
(accuracy = 75.6%, sensitivity = 66.7%, specificity = 84.6%) (Fig. 7b), which again 925 






Figure 7. (a) DF plot of the PCA-LDA model for the primary system (Operator 1); (b) DF 930 
plot of the PCA-LDA model for the primary system predicting the samples from the 931 
secondary system (Operator 2). 932 
 933 
(ii) Standardization. DS and PDS were employed as standardization methods. The 934 
number of transfer samples for DS was optimized according to the misclassification rate 935 
obtained for the validation set using the secondary system (Operator 2) (Fig. 8a). An 936 
optimum number of 59 transfer samples (30% of the samples in the training set of the 937 
primary system [Operator 1]) was obtained, resulting in a misclassification rate of 17.8% in 938 
the validation set of the secondary system. This improved the accuracy (82.2%), sensitivity 939 
(69.6%) and specificity (95.5%) compared to the results without DS. Fig. 8b shows the DF 940 
plot for the PCA-LDA model using the training of the primary system and prediction with the 941 
secondary system after DS. 942 
 The number of transfer samples was maintained as 59 for PDS; and the window size 943 
was optimized by using the validation set of the secondary system. An optimum window size 944 




accuracy, sensitivity and specificity using PDS were 77.8%, 100% and 54.5%, respectively. 946 
Although DS obtained an average better classification performance than PDS for this dataset, 947 
it also generated some outliers as mentioned before. For this reason, the results after PDS 948 
seem better standardized. The PCA-LDA DF plot after PDS is depicted in Fig. 8d. 949 
 950 
Figure 8. (a) Misclassification rate in % for the validation set of the secondary system 951 
(Operator 2) varying the number of transfer samples in % from the primary system (Operator 952 
1) for DS optimization; (b) DF plot of the PCA-LDA model for the primary system 953 
predicting the validation set from the secondary system after DS; (c) Misclassification rate in 954 
% for the validation set of the secondary system varying the window size for PDS 955 
optimization; (d) DF plot of the PCA-LDA model for the primary system predicting the 956 
validation set from the secondary system after PDS.  957 
 958 
Window size
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Supplementary Material 1 
 
Additional results from pilot study 
  
 S2
A. Effect of different instruments 
 
Figure S1. Average (a) raw and (b) pre-processed spectra for healthy controls samples; 
average (c) raw and (d) pre-processed spectra for cancer samples across three different 







A. Effect of different instruments 
 
Figure S2. (a) PCA scores for healthy control samples according to the instrument used for 
spectra acquisition (A, B and C); (b) PCA scores for cancer samples according to the 
instrument used for spectra acquisition (A, B and C); (c) Hotelling T2 versus Q residual test 
for healthy control samples according to the instrument used for spectra acquisition (A, B and 
C) based on a PCA using 5 PCs (94.77% cumulative variance); (d) Hotelling T2 versus Q 
residual test for cancer samples according to the instrument used for spectra acquisition (A, B 
and C) based on a PCA using 5 PCs (92.96% cumulative variance). Circled samples in (c) 







Figure S3. (a) PCA loadings for healthy control samples measured in different instruments 





B. Effect of different operators 
 
Figure S4. Average (a) raw and (b) pre-processed spectra for healthy control samples 
acquired with instrument A depending on the operator; average (c) raw and (d) pre-processed 
spectra for healthy control samples acquired with instrument B depending on the operator; 
average (e) raw and (f) pre-processed spectra for healthy control samples acquired with 





B. Effect of different operators 
 
Figure S5. Average (a) raw and (b) pre-processed spectra for cancer samples acquired with 
instrument A depending on the operator; average (c) raw and (d) pre-processed spectra for 
cancer samples acquired with instrument B depending on the operator; average (e) raw and 






B. Effect of different operators 
 
Figure S6. PCA scores for (a) healthy control and (b) cancer samples acquired with 
instrument A depending on the operator; PCA scores for (c) healthy control and (d) cancer 
samples acquired with instrument B depending on the operator; PCA scores for (e) healthy 
control and (f) cancer samples acquired with instrument C depending on the operator. 





C. Effect of different instruments and operators 
 
Figure S7. (a) Hotelling T2 versus Q residual test based on a PCA using 8 PCs (99.07% 
cumulative variance) for healthy control samples depending on the instrument for spectra 
acquisition (A, B and C) used by Operator 2; (b) Hotelling T2 versus Q residual test based on 
a PCA using 5 PCs (96.92% cumulative variance) for cancer samples depending on the 
instrument for spectra acquisition (A, B and C) used by Operator 2. Circled sample in a) 
indicates an outlier removed. The Hotelling T2 versus Q residual test for Operator 1 is 
depicted in Fig. S2c-d. 
  
 S9
D. Effect of different classes 
 
Figure S8. PCA scores for healthy controls (HC) and ovarian cancer (OC) samples based on 
the spectra acquired by both operators (1 and 2) and by all instruments (A, B and C). 
Confidence ellipse at a 95% confidence level is depicted in blue  
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A. Outlier detection using Hotelling T2 versus Q residuals test 
 
1st step: Build a PCA model. 
2nd step: Calculate Hotelling T2 and Q residuals. 
3rd step: Plot Hotelling T2 versus Q residuals 
4th step: Select the samples which are most distant to the plot origin (0,0) and remove them 
one at a time from the data set. This procedure can be performed manually after visual 
inspection or automatically by algorithms. 
Figure S1. Hotelling T2 versus Q residuals for healthy control samples (blood plasma) 
varying the instrument for spectra acquisition (A, B and C). PCA performed with 5 PCs 






B. Automatic outlier detection using MATLAB® 
 
Algorithm link to download: 
https://doi.org/10.6084/m9.figshare.7066613.v1  
 
1st step: Add the .m files within the file downloaded to the path. 
2nd step: Load the spectral data into MATLAB and organize all the spectra into a single 
matrix “X” containing each spectrum as a row. 
3rd step: Perform an initial PCA model to determine the number of principal components 
(PCs) to work with. 
4th step: Run the algorithm as follows: 
 
where “Xc” is the spectral matrix without outliers, “X” is the input spectral data, and “Npcs” 
the number of PCs for PCA. 
 5th step: Input optimization parameters: 
 
In this case, the algorithm will perform a PCA model 10 times removing one sample at a time 
that follows one of these criteria: Hotteling T2 > 25 or Q residuals > 0.8x10-3. Then, these 
samples are automatic excluded from the new dataset (Xc). The list of excluded samples is 
also displayed in MATLAB. Example: 
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